The firm now expects its cash runway to extend to 2028, bolstered by having recently raised $244 million via a private placement and an at-the-market issuance.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.

The EMA's CHMP said the single pivotal US trial could serve as the basis for a marketing authorization application in the EU.